Success Metrics

Clinical Success Rate
91.7%

Based on 22 completed trials

Completion Rate
92%(22/24)
Active Trials
1(4%)
Results Posted
50%(11 trials)
Terminated
2(7%)

Phase Distribution

Ph early_phase_1
1
4%
Ph phase_3
10
37%
Ph not_applicable
3
11%
Ph phase_2
8
30%
Ph phase_1
2
7%
Ph phase_4
3
11%

Phase Distribution

3

Early Stage

8

Mid Stage

13

Late Stage

Phase Distribution27 total trials
Early Phase 1First-in-human
1(3.7%)
Phase 1Safety & dosage
2(7.4%)
Phase 2Efficacy & side effects
8(29.6%)
Phase 3Large-scale testing
10(37.0%)
Phase 4Post-market surveillance
3(11.1%)
N/ANon-phased studies
3(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

91.7%

22 of 24 finished

Non-Completion Rate

8.3%

2 ended early

Currently Active

1

trials recruiting

Total Trials

27

all time

Status Distribution
Active(1)
Completed(22)
Terminated(2)
Other(2)

Detailed Status

Completed22
Terminated2
unknown2
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
27
Active
1
Success Rate
91.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (3.7%)
Phase 12 (7.4%)
Phase 28 (29.6%)
Phase 310 (37.0%)
Phase 43 (11.1%)
N/A3 (11.1%)

Trials by Status

terminated27%
completed2281%
recruiting14%
unknown27%

Recent Activity

1 active trials
Showing 5 of 27
completedphase_3

FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease

NCT01220843
recruitingphase_2

Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

NCT06664125
completedphase_2

A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients

NCT05764590
completedphase_3

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

NCT03427125
completednot_applicable

FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease

NCT00999037
View all 27 trials

Clinical Trials (27)

Showing 20 of 27 trialsScroll for more
NCT01220843Phase 3

FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease

Completed
NCT06664125Phase 2

Evaluate the Efficacy and Safety of JMKX003002 in End-Stage Renal Disease Patients on Hemodialysis with Hyperphosphatemia

Recruiting
NCT05764590Phase 2

A Study to Evaluate Safety and Efficacy of AP-306 in Hyperphosphatemia Patients

Completed
NCT03427125Phase 3

A Phase 3 Study of Tenapanor to Treat Hyperphosphatemia in ESRD Patients on Dialysis

Completed
NCT00999037Not Applicable

FGF-23 (Fibroblast Growth Factor 23) Regulation in Chronic Kidney Disease

Completed
NCT03988920Phase 4

A Long-Term Study of Tenapanor Alone or in Combination With Sevelamer in Patients With CKD on Dialysis and HP

Completed
NCT04551300Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of VS-505(AP301) to Treat Hyperphosphatemia in Hemodialysis Patients

Completed
NCT04120922Not Applicable

Assessing Bone Calcium Content in Children With Kidney Disease Treated With Two Different Medicines

Unknown
NCT03644264Phase 3

PA21 Safety and Efficacy in Adult Chinese Subjects

Completed
NCT03984760Phase 3

Ferric Citrate for the Treatment of Hyperphosphatemia in Patients With Chronic Kidney Disease Undergoing Hemodialysis

Completed
NCT04299633Phase 1

Study in Healthy Adult Subjects to Assess the Effect of Phosphate Binders on the Pharmacokinetics of a Single Dose of Vadadustat

Completed
NCT01543958Phase 2

Sevelamer for Reducing Endotoxemia and Immune Activation

Completed
NCT03596749Phase 3

The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4

Unknown
NCT01308242Early Phase 1

Effects of a Non-Calcium Based Phosphate Binder on FGF23 Levels in Chronic Kidney Disease

Completed
NCT01191762Phase 3

Sevelamer and Secondary Hyperparathyroidism in Chronic Kidney Disease

Completed
NCT01574326Phase 2

An Efficacy and Safety Study of Sevelamer Carbonate in Hyperphosphatemic Pediatric Participants With Chronic Kidney Disease

Completed
NCT01277497Phase 4

Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4

Terminated
NCT01427907Phase 4

Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

Completed
NCT00853242Phase 2

Randomized Study Comparing Genz-644470, Placebo, and Sevelamer Carbonate in Chronic Kidney Disease Patients on Hemodialysis

Completed
NCT00833768Phase 3

A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
27